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1. Introduction 
The discovery of the morphine-like peptide, beta- 
endorphin, which is identical to the sequence 61-91 
of beta-lipotropin (beta-LPH) [l-4] gave additional 
support to the idea that beta-LPH is a prohormone as 
suggested [5-71. In vitro biosynthetic experiments 
have demonstrated the production by pituitary tissue 
of betaendorphin, beta-LPH, and gamma-LPH (beta- 
LPH l-58) [8-lo]. It has been also suggested that 
an ACTHsecreting mouse pituitary tumor cell line 
(AtT-20/D-16V) synthesizes beta-LPH as a part of a 
larger precursor protein which contains the sequence 
of ACTH [ 1 l-l 31. We demonstrate here the existence 
of immunoreactive betaendorphin in the plasma of 
AtT-20 tumor-bearing mice and in extracts of these 
tumors. 
2. Materials and methods 
2 .l . Preparation of tumor extract and plasma 
The AtT-20 tumor [ 14.,15], obtained from Dr A. E. 
Bogden (Mason Research Institute, Worcester, MA), 
was periodically retransplanted in adrenalectomized 
LAFr mice. Two tumors (total wet wt 280 mg) were 
removed from mice killed by decapitation and imme- 
diately homogenized in 2 ml ice-cold 1 mM EDTA 
(PH 10.3), containing bovine serum albumin (fraction V, 
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GIBCO) (1 mg/ml) and bacitracin (Sigma Chemical) 
(500 ng/ml) by a Teflon@-glass homogenizer. After 
centrifugation (15 min, at 15 000 rev./min, 4’C), the 
supernatant was frozen at -20°C. 
Trunk blood was collected into ice-cold tubes con- 
taining EDTA and aprotinin (Trasylol@, Boehringer 
Ingelheim Canada Ltd) (final concentrations: 2 mg 
and 500 kIU/ml blood, respectively). Plasma was 
separated by centrifugation (10 min, 4000 rev./mm 
4’C), and frozen at -20°C. Plasma from adrenalecto- 
mized LAFr mice was used as control. Both tumor 
extract and plasmas were stored at -20°C until 
further studies. 
2.2. Beta-endolphin radioimmunoassay 
The details of our procedure have been described 
[ 16,171. Antiserum against beta-endorphln was kindly 
supplied by Dr Roger Guillemin, Salk Institute, LaJolla, 
CA. It cross-reacts with beta-LPH (58% on a molar 
basis) (tig.lA), but does not with gamma-LPH, beta- 
MSH, ACTH or alpha-MSH. Ovine beta-endorphin, 
isolated and purified as in [ 181, was used as tracer 
and standard. Tumor extract and plasma samples 
were assayed in duplicate at several dilutions. The dis- 
placement curves were linearized by log-logit transfor- 
mation. Weighted least squares regression lines were 
fitted and parallel-line potency estimates made by the 
procedure in [19]. 
2.3. Gel filtration 
Samples of tumor extract (10 /.d) or plasma of 
tumor-bearing mice (200~1) were applied to a 1 X 55 cm 
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Fig.la. Anti-betaendorphin serum specificity: cross-reactivity with beta-LPH. Fig.lb. Displacement curves for tumor extract and 
plasma of tumor-bearing adrenalectomized mice parallel to the standard curve. 
Sephadex@ G-50 superfine column, equilibrated and 
eluted with 0.01 M phosphate, 0.15 M NaCl, 0.025 M 
EDTA,O.OOl%merthiolate, I’% bovine serum-albumin, 
pH 7.6, buffer. One ml fractions were collected and 
assayed for betaendorphin immunoreactivity . The 
column was calibrated with ferritin (void volume), 
?I-labeled beta-LPH and r2’I-labeled betaendorphin. 
TUMOR EXTRACT PLASMA 
!kl1- - 
P-LPH 
3. Results 
As illustrated in iig.lB, immunoreactive (IR)-beta- 
endorphin is present in AtT-20 tumor extracts as well 
as in plasma of tumor-bearing mice. Both displacement 
curves were parallel with the standard betaendorphin. 
The tumor tissue contains 11.3 ng/mg wet wt (95% 
confidence interval, 10.9-l 1.7) and the plasma 
785 ng/ml(760-810) of IR betaendorphin. Plasma 
of adrenalectomized mice contains 4.5 ng/ml(4.3-4.7). 
Figure 2 shows the molecular weight distribution 
FRACTION NlJMEERf I”,, , 
Fig.2. Elution profiles of immunoreactive betaendorphin 
from Sephadex G-50 superfine chromatography for AtT-20 
tumor extract and plasma of AtT-20 tumor-bearing adrenal- 
actomized mice. Elution volumes of beta-LPH and beta- 
endorphin are shown. 
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of IR betaendorphin in both tumor extract and plas- 
ma, as obtained by gel filtration on a Sephadex G-50 
superfine column. Two major peaks are separated; the 
first one corresponds to the elution volume of ovine 
beta-LPH and the second one to betaendorphin. The 
relative size of these 2 peaks differs in tumor extract 
and plasma samples. 
4. Discussion 
This study provides evidence that the AtT-20 
tumor secretes immunoreactive b taendorphin. The 
AtT-20 tumor has been shown to contain different 
forms of ACTH [20-221 and MSH [20]. Likewise, 
the production of immunoreactive b taendorphin by 
the rat transplantable pituitary tumor MtT-F4 which 
is known to secrete ACTH has been described [17]. 
Immunocytochemical studies have pointed out the 
presence of ACTH, beta-LPH and betaendorphin i  
the same cells of anterior and intermediate pituitary 
lobes [23,24]. The biosynthesis of a common precur- 
sor (31 K) to betaendorphin and ACTH [lo-121, as 
well as betaendorphin and ACTH-like peptides was 
demonstrated byexperiments using the AtT-20/D-16V 
cell line [25]. Our results upport he concept of a 
concomitant secretion of betaendorphin and ACTH 
VI. 
The immunoreactive b taendorphin secreted by 
AtT-20 tumors appears to be present in 2 major 
molecular forms. The first one has a molecular weight 
corresponding to that of standard ovine beta-LPH, 
while the second one corresponds to betaendorphin 
itself. In agreement with structural relationship and 
common immunoreactivity of beta-LPH and beta- 
endorphin, it is reasonable to believe that the higher 
molecular weight component is in fact beta-LPH. The 
precursor nature of this higher molecular weight com- 
ponent is also suggested by the relative increase of the 
lower molecular weight component in plasma s com- 
pared to tumor tissue extract. This relative increase of 
beta-endorphin i  plasma may be a consequence of
preferential secretion of the smaller peptide and/or 
peripheral cleavage of beta-LPH to betaendorphin. 
On one hand, the latter alternative issupported by in 
vivo demonstration of cleavage of beta-LPH into beta- 
endorphin in rabbits injected with purified ovine 
beta-LPH [27]. On the other hand, AtT-20/D-16V 
cultured cells [ 11,251 and AtT-20 tumor Isolated cells 
(unpublished results) synthesize betaendorphin and 
release it into incubation medium in relatively low 
concentrations. Secondary degradation of beta-LPH 
during manipulation of the plasma is very improbable 
because all studies were performed at 4°C with a 
protease inhibitor (Aprotinin). It was also demonstrated 
in rabbits [27] that beta-LPH has a significantly lower 
disappearance rate than betaendorphin. This could 
explain persistent beta-LPH-like material in plasma. 
The presence of a relatively low peak of high molec- 
ular weight IR-betaendorphin (fig.2) in plasma nd in 
tumor extract could be explained either by some 
degree of aggregation r by the presence of a 20-30 K 
precursor form of both ACTH and beta-LPH [2122]. 
The high level of betaendorphin in the plasma of 
AtT-20 tumor-bearing mice might influence pain 
sensitivity and induce a state similar to opiate tolerance- 
dependence [28,29]. This would require passage of
the peptide from the circulation of the brain across 
the blood-brain barrier to reach central nervous ys- 
tem opiate receptors. Such a phenomenon has been 
suggested by the observation of analgesia following 
intravenous injection of a high dose of betaendorphin 
in mice [30]. In rabbits, betaendorphin crosses the 
blood-brain barrier into the CSF [27]. An increase in 
brain betaendorphin levels could be expected from 
this hypothesis, although the absence of a parallel 
between blood and brain levels of betaendorphin 
immunoreactivity has been established following 
adrenalectomy in rat [31]. The behavior of these 
tumor-bearing mice is not grossly affected. 
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